NCCN Guidelines® Insights - Acute Myeloid Leukemia, Version 2.2013

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia (AML) and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, feature recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and provide guidance on maintenance strategies for APL.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for AML
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for AML
Additional information
Supporters: 

Supported by educational grants from ARIAD Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.; CELGENE CORPORATION; Eisai Inc.; Endo Pharmaceuticals and HealthTronics; Genentech; Millennium: The Takeda Oncology Company; and Teva Pharmaceuticals

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
09/19/2013
Course expires: 
09/19/2014
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
09/19/2013
Course expires: 
09/19/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing